Update shared on 26 Nov 2025
Analysts modestly raised their price targets for Intuitive Surgical, with recent updates clustering in the $525 to $603 range. They cited stronger-than-expected quarterly results and robust demand supporting profitability, despite ongoing sector volatility.
Analyst Commentary
Recent analyst updates on Intuitive Surgical reflect a mixed view of the company's prospects following its quarterly results. While optimism is evident around profitability and demand trends, certain risks and cautionary signals remain at the forefront.
Bullish Takeaways- Bullish analysts highlighted better than expected quarterly performance, especially in revenue and earnings per share growth, supporting higher price targets.
- Strong demand for Intuitive Surgical's products and improved operating leverage contributed to profitability exceeding initial expectations.
- Encouraging management commentary, particularly on procedural utilization trends, reinforced confidence in ongoing growth execution.
- Valuation adjustments following recent earnings suggest that market participants recognize the company's underlying momentum, prompting upward price target revisions.
- Cautious analysts maintain Hold ratings, viewing current positive expectations as largely priced into the stock and reflecting a balanced risk-reward outlook.
- Ongoing margin pressure, partially due to tariffs and mix, raises questions around sustainable profitability despite recent upside surprises.
- Broader MedTech sector volatility and the apparent lack of new investor capital amplify concerns about potential stock price fluctuations going forward.
- Crowded positioning and heightened sensitivity to earnings results may lead to exaggerated share price moves, making the stock more reactive to even minor deviations from expectations.
What's in the News
- Completed a share repurchase of 4,002,556 shares between July and September 2025, bringing the total repurchased shares to 26,673,795 since 2015. This represents 7.56% of shares and totals $7.75 billion. (Key Developments)
- The U.S. FDA cleared software advancements for the Ion endoluminal system, introducing artificial intelligence features and enhanced imaging capabilities designed to improve accuracy and efficiency of lung biopsies. An initial limited launch is planned, with a broader U.S. release expected in 2026. (Key Developments)
- New software capabilities were announced for the da Vinci 5 surgical system, including Force Gauge, In-Console Video Replay, and Network CCM for remote software updates. These features are intended to boost efficiency, support decision-making, and enhance procedural safety, with all receiving FDA 510(k) clearance. (Key Developments)
Valuation Changes
- Fair Value remains steady at $592.96 per share, indicating no change from previous estimates.
- Discount Rate decreased marginally from 7.70% to 7.70%, suggesting a slightly more favorable risk assessment by analysts.
- Revenue Growth projection is stable at 13.48% annually, reflecting consistent expectations for top-line expansion.
- Profit Margin estimate holds near 30.33%, with virtually no change, pointing to maintained confidence in operating efficiency.
- Future P/E ratio declined modestly from 60.69x to 60.51x, representing a minor adjustment in forward valuation assumptions.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.